Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$139.93 USD

139.93
30,973

-0.01 (-0.01%)

Updated Oct 9, 2024 10:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment

by Zacks Equity Research

Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.

Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring

by Zacks Equity Research

Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.

Varian Medical Buys Endocare & Alicon to Boost Cancer Care

by Zacks Equity Research

Varian Medical (VAR) expects the buyouts to prove accretive to bottom line in fiscal 2020.

HealthEquity (HQY) Earnings & Revenues Top Estimates in Q1

by Zacks Equity Research

Higher revenues, solid segmental performance and expansion in margins benefit HealthEquity's (HQY) Q1 earnings.

Why Is Masimo (MASI) Down 2.9% Since Last Earnings Report?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cooper Companies (COO) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and expansion in margins benefit Cooper Companies' (COO) Q2 earnings.

Veeva Systems (VEEV) Q1 Earnings Top Estimates, View Strong

by Zacks Equity Research

Veeva Systems (VEEV) issues strong guidance for fiscal 2020.

NextGen's (NXGN) Q4 Earnings Top Estimates, Bookings Down Y/Y

by Zacks Equity Research

NextGen (NXGN) Q4 results benefit from better performing recurring segment. However, gross margin contraction remains a woe.

Masimo's Technologies to be Deployed to Boost Pediatric Care

by Zacks Equity Research

NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.

Globus Medical Reveals Positive Study Results for ExcelsiusGPS

by Zacks Equity Research

Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure

Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises

by Zacks Equity Research

Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.

Here's Why You Should Hold On to Integra LifeSciences Stock

by Zacks Equity Research

Investor confidence is still high on growth prospects of Integra LifeSciences (IART).

    QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access

    by Zacks Equity Research

    This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.

    Hologic Breast Health Arm Aids Strongly, Rising Costs Ail

    by Zacks Equity Research

    Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.

    Will RTG Again Bolster Medtronic's (MDT) Earnings in Q4?

    by Zacks Equity Research

    Within Neurovascular, we hope to witness strength across Medtronic's (MDT) stroke franchise with growth in stent retrievers, flow diverters, neuro access and embolic products.

    ResMed Study Shows Remote Monitoring Benefits on CPAP Use

    by Zacks Equity Research

    Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.

    Here's Why You Should Buy Masimo (MASI) Stock Right Now

    by Zacks Equity Research

    Masimo (MASI) benefits from launches like Halo ION.

    Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring

    by Zacks Equity Research

    Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.

    Avedro (AVDR) Hits a 52-Week High on Solid Growth Prospects

    by Zacks Equity Research

    Avedro (AVDR) gains from promising developments in recent times.

    Varian Medical's CTSI Buyout to Boost Oncology Services Unit

    by Zacks Equity Research

    The CTSI buyout is expected to prove accretive to Varian Medical's (VAR) adjusted earnings per share during fiscal 2021.

    Why Should You Hold on to Myriad Genetics (MYGN) Stock?

    by Zacks Equity Research

    Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).

    LabCorp Grows on Strong Diagnostics Arm Amid Contract Losses

    by Zacks Equity Research

    LabCorp's (LH) diagnostics business grows organically despite additional price reductions.

    Medtronic (MDT) Launches Telescope Guide Extension Catheter

    by Zacks Equity Research

    The launch of Telescope marks Medtronic's (MDT) foray into the guide extension catheter market.

    ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

    by Zacks Equity Research

    ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

    QIAGEN Partners Inovio to Develop Companion Diagnostics

    by Zacks Equity Research

    QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.